优化慢性乙型肝炎患者停用核苷(酸)类似物后复发的预测
该回顾性研究纳入488例停用核苷(酸)类似物的慢性乙型肝炎患者,中位随访73.3个月,发现治疗结束时HBsAg水平、巩固治疗时长及肝硬化是停药后复发的关键决定因素,联合这些参数可提高现有停药规则的预测能力。
要点
- 治疗结束时HBsAg水平与巩固治疗时长是HBeAg阳性患者病毒学复发的独立预测因素。
- HBeAg阴性患者仅HBsAg水平独立预测复发,肝硬化患者低HBsAg水平时复发率更高。
- 联合HBsAg水平与现有停药规则或巩固时长可降低复发,HBeAg阳性2年复发率约15%-25%。
核心结论
- 治疗结束时HBsAg水平、巩固治疗时长和肝硬化是停药后复发的关键决定因素。
- 联合这些参数有助于识别低复发风险个体并显著提高现有停药规则的预测能力。
研究设计与样本
- 回顾性研究,纳入488例停用核苷(酸)类似物的慢性乙型肝炎患者,其中HBeAg阳性262例、HBeAg阴性226例。
主要发现
- 中位随访73.3个月,累计5年和10年病毒学复发率分别为73.5%和76.1%。
- HBeAg阴性患者中,仅HBsAg水平(HR 1.61,95%CI 1.24-2.11)独立预测病毒学复发。
- HBeAg阴性且HBsAg水平低(≤800 IU/mL)的患者中,肝硬化与更高的病毒学复发率显著相关。
- 联合治疗结束时HBsAg水平与现有停药规则或巩固时长,HBeAg阳性患者2年病毒学复发率约15%-25%,HBeAg阴性患者约35%。
关键数值与推荐
- HBeAg阳性患者巩固治疗≥2年且HBsAg水平低(≤560 IU/mL)可显著降低病毒学复发率。
- HBeAg阴性患者HBsAg水平≤800 IU/mL时,合并肝硬化者病毒学复发率更高。
临床怎么用
- 应确保巩固治疗≥2年,尤其对于HBsAg水平低的患者。
- 肝硬化患者即使达到低HBsAg水平,也应继续核苷(酸)类似物治疗。
- 联合治疗结束时HBsAg水平、巩固时长和肝硬化状态可优化停药决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines recommend rules for stopping nucleos(t)ide analogues (NAs) in patients with chronic hepatitis B (CHB), but off-therapy relapse is still high. This study aimed to identify predictors of off-therapy relapse and improve existing stopping rules. METHODS: This retrospective study included 488 patients with CHB (262 hepatitis B e antigen [HBeAg]-positive and 226 HBeAg-negative) who discontinued NAs. Posttreatment relapse was investigated. RESULTS: During the median follow-up period of 73.3 months, the cumulative 5-year and 10-year virologic relapse (VR) rates were 73.5% and 76.1%, respectively. In HBeAg-positive patients, end-of-therapy hepatitis B surface antigen (HBsAg) levels (hazard ratio [HR], 1.93 [95% confidence interval {CI}, 1.42-2.61]) and consolidation duration ≥2 years (HR, 0.31 [95% CI: .17-.58]) were independent predictors of VR. Consolidation ≥2 years and low HBsAg levels (≤560 IU/mL) significantly lowered VR rates. In HBeAg-negative patients, only the HBsAg level (HR, 1.61 [95% CI: 1.24-2.11]) was independently predictive of VR. Cirrhosis was significantly associated with higher VR rates in HBeAg-negative patients with low HBsAg levels (≤800 IU/mL). Combining end-of-therapy HBsAg levels with current stopping rules or consolidation duration further reduced off-therapy relapse, with 2-year VR rates of approximately 15%-25% in HBeAg-positive patients and 35% in HBeAg-negative patients. CONCLUSIONS: End-of-therapy HBsAg levels, consolidation duration, and cirrhosis are key determinants of off-therapy relapse. Together with low HBsAg levels, extended consolidation therapy for ≥2 years should be ensured, and cirrhotic patients should continue NAs even if low HBsAg levels are achieved. A combination of these parameters will help identify individuals at low risk of relapse and significantly improve the predictive ability of the existing stopping rules.
引用
- Song DS, Jang JW, Yoo SH, et al. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis. 2021. PMID: 33417679. doi:10.1093/cid/ciab007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。